• Splash Beverage Group acquired Copa Di Vino for $5.98 million in December 2020
• Copa Di Vino specializes in selling premium wine by the glass, a format which has grown in popularity in recent years
• With wine being increasingly consumed outside of restaurants, hospitality venues over past year, the Copa Di Vino acquisition provides SBEV with an avenue by which to capitalize on growing retail, online sales channels

Splash Beverage Group (OTCQB: SBEV), a holding company for a leading portfolio of beverage brands, completed the acquisition of James Martin’s Copa Di Vino on December 28, 2020 – marking Splash Beverage’s entry into the lucrative wine market (https://ibn.fm/hLnfp). The Copa di Vino acquisition, which SBEV agreed to purchase for a total consideration of $5,980,000 in addition to assuming certain liabilities, will mark the addition of a fourth premium brand to Splash Beverage’s portfolio, which already includes isotonic drink, TapouT Performance, tequila brand Salt Naturally Flavored Tequila and Pulpoloco Sangria from Spain, which comes in a sustainable innovative package that is both recyclable and biodegradable. The United States wine industry saw total sales by value decline by between -0-2% percent in 2020, largely a result of widespread restaurant and hospitality closures. However, overall wine sales growth still outpaced the performance seen in the smaller premium wine segment, a category habitually associated with restaurant consumption, which saw sales decline by between -5 and -10 percent over the course of the year (https://ibn.fm/IkKGd). Nonetheless, despite a tumultuous year, certain segments of the American wine market have witnessed tremendous gain. Retailers with strong online sales strategies, wineries focused on Zoom tastings and phone sales, and wineries selling their products in novel packaging formats have all profited from robust sales figures resulting from the shelter-in-place orders, work-from-home trends and restaurant closures (https://ibn.fm/Rbmzf). “Wine was added back to the family dinner table, and consumers adapted to online shopping and at-home delivery,” said Rob McMillan, founder of the Silicon Valley Bank Wine Division. “While many stocked up on everyday wines at the supermarket, consumers also rapidly switched to online options, either because their selections weren’t available in grocery stores or because doorstep delivery was viewed as safer,” he continued. Copa Di Vino has been a significant beneficiary of the increased tendency for consumers to consume wine outside of traditional hospitality venues as well as in smaller, single-serve volumes. The company, a leading producer of premium wine by the glass in the United States, has looked to specialize in providing consumers with a ready-to-drink wine glass designed to go anywhere without the need for a bottle, corkscrew, or glass. “We are extremely excited and proud to add Copa di Vino to the SBG portfolio of brands,” Splash Beverage Group CEO Robert Nistico noted in relation to the company. “In addition to numerous retail/off premise opportunities, Copa is perfectly suited for today’s on-premise/restaurant & hotel environment of curbside pickup. Copa Di Vino offers an outstanding quality product not normally found in the single serve wine segment.” Having gained immense popularity after featuring on two separate appearances on the Shark Tank television show, Copa Di Vino’s selection of premium wines is distributed across 13,000 retail locations across the United States as well as through the Anheuser-Busch network, in addition to e-commerce outlets. With industry analysts IWSR forecasting wine sales to rise by a CAGR of 2.4% between 2020 and 2024, Copa Di Vino and Splash Beverage Group seem well placed to benefit. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• AABB launches AABB Gold cryptocurrency token, AABB Wallet targeting high-growth markets
• Initial token release is 100% backed by $30 million in physical gold
• Company plans to expand token circulation through mine-to-token vertical integration

Asia Broadband (OTC: AABB), a resource company focused on the production, supply and sale of precious and base metals primarily to the Asian market, has launched its AABB Gold (AABBG) cryptocurrency token (https://ibn.fm/j1FDQ). Intended to become a secured and trusted gold-backed global standard of exchange, the token was developed in collaboration with Core State Holdings Corp. (“CSHC”).

Gold-backed cryptocurrency is a type of crypto stablecoin backed with physical gold and with the price pegged to the current gold price. As such, these tokens tend to have less price fluctuation than other coins such as Bitcoin (https://ibn.fm/x4tqP). With that in mind, AABB announced that its initial token release is backed 100% by $30 million in physical gold the company currently holds. Because the token price is generally tied to the market price of gold at a minimum, when the price of gold changes, the minimum supported price of the AABBG token will change. However, the potential upside price of the token will be driven by market demand.

The company is proceeding to implement an international marketing campaign aimed to proliferate brand exposure, increase token sales and AABB Wallet transactions, and amplify public and investment community awareness of the company. AABB’s primary goal for the token is to become a worldwide standard of exchange that is secured and trusted with gold backing, by progressively expanding token circulation to the primary sales markets  of North America and Europe and expand globally to other predominant   and high-growth market areas.

AABB’s cryptocurrency project is based on what the company calls a mine-to-token vertical integration operational approach that aims for complete independence from FIAT currency. The tokens are available for purchase only in exchange for other major cryptocurrencies including Bitcoin, Ethereum and Litecoin that buyers hold in third-party wallets such as Coinbase or Binance.

In order to make the transaction, buyers will transfer cryptocurrency from their third-party wallets into their AABB Wallets to purchase AABBG tokens; current price per token is 0.1 gram of gold (approximately $5.60) plus a small transaction fee. While the subsequent transfer of AABBG tokens between users of AABB Wallets will be possible, the tokens will not initially be exchangeable for other cryptocurrencies within the initial AABB Wallet. Before any transaction, AABB Wallet users will need to install the latest version of the app and pass the Know Your Client (“KYC”) process.

The launch version of the AABB Wallet will allow the company to increase token circulation and accumulate revenues to support and stabilize the token price when AABBG is freely tradable in the open market, after the company launches its proprietary exchange version of the AABB Wallet in coming months.

With this milestone launch, AABB appears poised to further advance its cryptocurrency project. The company is continuing to team with CSHC to further develop its proprietary cryptocurrency exchange, with a focus on allowing more efficient and easy exchange of AABBG tokens for major cryptocurrencies such as Bitcoin, Ethereum and Litecoin. The company has also joined forces with CSHC to launch an international marketing campaign for its cryptocurrency project, designed to enhance the general public and investment community’s awareness of the AABBG token and the AABB Wallet.

For more information, visit the company’s website at www.AsiaBroadbandInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• Pure Extracts plans affiliate partnership to install cannabis and hemp extraction system in existing Michigan facility
• Company CEO notes excitement about launching into first US initiative with experienced and entrenched partners
• Agreement outlines planned renovation of existing 2,600-square-foot facility located in central Michigan

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, has inked a letter of intent (“LOI”) to form a joint venture that paves the way for the company’s entrance into the United States. Based on the LOI, PULL will partner with the affiliate of a publicly traded multi-state operator (“MSO”) to install a cannabis and hemp extraction system in an existing Michigan facility.

“We are really excited about launching our first US initiative into the dynamic Michigan market, especially with experienced and entrenched partners,” said Pure Extracts’ CEO Ben Nikolaevsky. “There is strong demand throughout the state for the products we know best: full spectrum oil (‘FSO’) vapes, live resin concentrates and edibles. With immediate access to the MSO affiliate’s 100+ dispensary customers out of Michigan’s nearly 400 licensed dispensaries, we expect our products to be distributed and on shelves in Q4 of this year.”

Pure Extracts’ JV announcement noted that its MSO partner has a history of success in Oregon offering a variety of products including sun-grown and indoor premium flower, along with patented nitro-sealed indoor and sun-grown pre-rolls and jars. The MSO also grows and packages the same products in Michigan; the products are sold in more than 100 retail dispensaries located throughout the state.

According to the LOI, the two companies intend to renovate 2,600-square-feet of underutilized space within the existing facility located in central Michigan, where some of the state’s most promising cannabis markets are within two hours. The JV will combine Pure Extracts’ extraction, vape, live resin and edibles manufacturing skills with the MSO affiliate’s local permitting, licensing, and marketing expertise to deliver a line of high-quality products that are ideally suited for Michigan’s cannabis consumers. In addition to Pure Extracts’ exclusive product lines of vapes and edibles, the partners plan on an initial white-label order for live-resin concentrates from the MSO affiliate, which is planning to build-on the exceptional reputation its products have already gained within the Michigan marketplace.

Pure Extracts noted in the announcement that it anticipates contributing a mix of equipment and cash to the JV. The intent is for the JV to scale-up to meet the rising demand for recreational cannabis concentrates and edibles throughout the state.

“Michigan is one of the fastest-growing cannabis markets in the U.S,” said Bruce Linton in a recent Forbes article. Linton was a co-founder and former CEO of cannabis giant Canopy Growth and is currently executive chairman of Michigan-based cannabis company Gage Growth Corp. His comment is validated by the state’s recent reported numbers.

According to the Michigan Marijuana Regulatory Agency (“MRA”), in February 2021, Michigan cannabis sales increased 160% from the previous February, reaching an estimated $106.2 million. Those numbers show medical sales improving 48% to $38.1 million and adult-use sales seeing triple digit growth, totaling more than $68 million, which is a 353% increase. These numbers follow similar patterns seen in other states such as California and Colorado, where sales of extracts and concentrates have overtaken sales of dry flower.

Pure Extracts is dedicated to developing its portfolio of cannabis 2.0 products. The company is particularly focused on its 34 proprietary formulations of Pure Pulls branded full-spectrum oil (“FSO”) vape products and on its new line of Pure Chews edible gummies.

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming toward export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. In September of last year, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. The company’s stock began trading on the Canadian Securities Exchange (“CSE”) in November 2020.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Plant-based supplements gaining popularity for treating chronic cardiovascular and neuro ailments
• Healthy Extracts, Inc. intensifies its foothold through its subsidiaries BergaMet North America and Ultimate Brain Nutrients
• The company recently announced positive results of clinical studies for two leading products, BergaMet North America’s HERHEART(TM) and UBN’s Fuel4Thought(TM) Brain Booster

Plant-based diets (“PBD”) decrease the serum levels of inflammation by reducing levels of ROS (https://ibn.fm/tA2MU). Also, chronic neuropathic pain is a common debilitating problem and its treatment presents a major challenge to health care. Studies indicate that plants and some constituents of herbal medicine have the potential to cure neuropathic pain (https://ibn.fm/YjtYW). Healthy Extracts (OTCQB: HYEX) is a leading researcher and manufacturer of plant-based formulations offering healthy supplements that are beneficial for heart and nerve health. The company continues to strengthen its stronghold in the health and lifestyle industry through its unique assets and operations of subsidiaries BergaMet North America and Ultimate Brain Nutrients (“UBN”). BergaMet NA operations are centered around the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit™ called “bergamot.” Bergamot is uniquely loaded with various antioxidant polyphenols. This Mediterranean fruit supports heart health, reduces stress, anxiety, and improves metabolic health with no known side effects. The only Citrus Bergamot SuperFruit(TM) heart health supplement backed by 17 clinical studies (https://ibn.fm/Tcmyr), the BergaMet brand supplement is enriched with the world’s best quality polyphenols and flavonoids, benefiting the lives of thousands of people who suffer from heart ailments. It is also the only Bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. Healthy Extracts acquired BergaMet NA in 2019, the only company authorized to manufacture, distribute, and sell these products in the United States, Canada, and Mexico. This acquisition move further strengthened Healthy Extracts’ foothold in the broader health industry. Healthy Extracts Inc. recently announced positive results of clinical studies for two leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. Duke Pitts, CEO of BergaMet North America, stated that HER HEART(TM) is a natural supplement that is scientifically formulated specifically for women to support cardiovascular health, including perimenopausal symptoms (https://ibn.fm/oqbRG). Cardiovascular disease is the number one cause of death for women in the U.S. The company expects HERHEAT(TM) to become one of its top-selling products, under the leadership of the internationally renowned health expert Dr. Nesochi Okeke-Igbokwe MD., M.S, who recently joined the company’s Medical Advisory Board. The company’s UBN subsidiary released its study of Fuel4Thought(TM) Brain Booster, showing impressive results in brain activation, sports vision, hand to eye coordination, and auditory reaction time (https://ibn.fm/lgMuj). For more information, visit the company’s website at www.HealthyExtractsInc.com. NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

• Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system
• TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development
• Company is global developer of world-class, innovative technologies using 3D cell culture, media

In the treatment of cancer, most patients receive standard one-size-fits-all drug treatments identified from studying the cancers, treatments and results of other patients. In the evolving world of personalized oncology, the approach entails testing a variety of potential drugs on a patient’s unique tumor to discover which drug, or combination of drugs, might work best. That is precisely the approach that Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis, takes in addressing ovarian cancer.

According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system (https://ibn.fm/D1TkL). The ACS estimated that in 2021, more than 21,000 women will be diagnosed with ovarian cancer, with more than 13,000 women dying from it.

The standard of care for ovarian cancer patients is the use of cisplatin, or carboplatin, in combination with taxol in alternating treatments following surgery weekly with intraperitoneal and intravenous infusions of the two different drugs, one IV and the other IP, then alternating; only 40–50% of patients survive past five years (https://ibn.fm/BW5uS). TumorGenesis, through its proprietary TumorGenesis tumor modeling, is confident it can provide pharmaceutical companies newfound ability for more effective and expeditious drug development and, as a result, improve patient outcomes.

That’s a lofty claim, but one that TumorGenesis can back up with its innovative personalized oncology approach. The company is a global developer of world-class and innovative technologies using 3D cell culture and media; the company specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using cancer samples that reflect the actual tumors found in a patient.

This idea of personalized oncology isn’t unique to TumorGenesis; however, personalized oncology has been generally unsuccessful in the past because cell lines can only be established from less than 1% of all ovarian cancers. TumorGenesis technology enables cell lines from patients to represent more than 90% of patient tumors that the current 1% of ovarian cancer cells available for research don’t represent — numbers that are transformative for ovarian cancer patient treatments.

The result, simply stated, assists health providers in selecting the most effective drug to treat a specific patient’s unique cancer — personalized medicine at its finest.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SRAX Inc released its unaudited financial results for 4QFY2020 on March 29, 2021
• The company reported Q4 revenues of $4.5 million, up 316% YoY whilst also revealing that it had achieved $200 thousand in net income in final quarter of the year
• SRAX’s Sequire platform saw the number of corporate subscribers on its platform increase to 183 companies (vs 92 companies as of Q3)
• SRAX raised its sales guidance for FY2021 to $23-25mn, implying YoY growth rate of 164-187%

SRAX (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, released its unaudited financial results for the fourth quarter of 2020 on March 29, 2021 (https://ibn.fm/TYdrY). The company reported Q4 revenues of $4.5 million, up 316% year-over-year, while reporting net income of $200,000 over the same period. Key Highlights:

• SRAX reported Q4 revenues of $4.5 million, up 316% year-over-year and up 74% quarter-on-quarter
• SRAX reported Q4 net income of $200,000, a significant increase relative to the net loss of -$4.4 million witnessed in Q4 of 2019
• SRAX reported FY2020 revenues of $8.7 million, an increase of 141% year-over-year relative to the 2019 fiscal year
• SRAX reported FY2020 net income of -$14.7 million, with the net loss narrowing compared to FY2019’s -$16.9 million.
• SRAX revealed that the company’s gross margins for Q42020 had risen to 73% (versus 70% for FY2020 and 44% for Q42019)

In addition to releasing its fourth quarter and FY2020 results, SRAX also seized upon the opportunity to provide its shareholders and the market with a series of operational updates as to the ongoing status of its business. SRAX raised its FY2021 sales guidance from $17-$18 million previously to $23-25 million, a substantial increase implying a growth rate of between 164 – 187% year-over-year for FY202, with the company revealing that Sequire, its investor intelligence SaaS platform, had enjoyed a remarkable uptick in its business operations, recording its eighth consecutive quarter of growth. Sequire secured bookings of $4.8 million and $10 million for the fourth quarter of 2020 and first quarter of 2021, respectively, while also seeing its corporate subscriber base swell to 183 publicly listed companies, up from 92 companies as of their Q3 2020 update. In addition to its new corporate clients, SRAX announced that Sequire would recognize $16.5 million in revenues based on its existing contracts over the course of the 2021 fiscal year. While SRAX’s organic revenue growth was impressive in its own right, the company also revealed that it had generated gross proceeds of $8 million through the sale of a position in TI Health (formerly known as SRAXmd). In addition, the company also added that it held approximately $23.8 million worth of publicly listed securities which it would potentially seek to monetize in the future. “We are making great progress with our platform and we are seeing continued adoption of the products that we are building for issuers. We had another record quarter of bookings for Sequire. In the first quarter of 2021 we have closed over $10 million in contracts,” stated SRAX Founder and CEO Christopher Miglino following the results announcement. “Our team did an amazing job in delivering a number of cutting-edge technological improvements to the platform and they have laid the foundation for some amazing enhancements that we will bring to market throughout the rest of this year.” For more information, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• The PSA campaign leveraged front-line staff real-life stories, insight and practices to raise awareness of dedicated support service tools
• Campaign’s success in generating engagement and reach prompted requests for additional similar endeavors in the near future
• DGTL and subsidiary Hashoff recently began a second activation campaign for a prominent digital sports gaming and entertainment brand following the success of an NCAA March Madness tournament-themed video-based social media campaign
• DGTL remains committed to building a full-service AI-powered digital media, marketing and advertising software platform to serve virtually every industry

DGTL Holdings (TSX.V: DGTL) (OTCQB: DGTHF) (FSE: A2QB0L), an innovative company focused on the acquisition and acceleration of transformative digital media, marketing and advertising software technologies, via wholly owned subsidiary Hashoff LLC, recently completed a campaign designed to promote an online support service portal and to help build social community among front-line healthcare professionals. According to a company press release, the national public service announcement campaign was conducted jointly with a task force comprised of top professional advocacy organizations in healthcare and led by an organization that has been advocating for the interests of registered nurses nationwide for more than a century (https://ibn.fm/NPvf3). The task force was created with the goal of developing and deploying online tools in support of healthcare workers dealing with mounting workplace challenges and pressures as a result of the ongoing pandemic. Hashoff, an enterprise-level self-service content-as-a-service offering built on proprietary artificial intelligence and machine learning technology, leveraged its platform to create an advocacy campaign that included content generated by the healthcare community, with the goal of creating awareness and promoting adoption of dedicated tools. The campaign focused on publishing unique real-life stories, key insights and best practices of healthcare professionals, while aiming to drive traffic to an online portal with support services for front-line workers. According to DGTL Holdings, the campaign was highly successful in generating engagement and reach, as well as gratitude from healthcare workers toward the organizations providing these support tools. The success of this endeavor has also led to multiple requests for additional campaign proposals from the task force and its members. This project is representative of Hashoff’s commitment to empower global brands by identifying, optimizing, engaging, managing and tracking digital content publishers for marketing campaigns through its proprietary AI-ML platform. Just a day before announcing the completion of this campaign geared towards healthcare professionals, Hashoff activated a new mobile social content campaign for a prominent digital sports gaming and entertainment brand (https://ibn.fm/OBa49). This is the second campaign activation under the multiyear software licensing agreement Hashoff signed with this brand. It will include self-serve and managed-service products, and will create and distribute multimedia mobile social creative content with the client’s branding and a 2021 PGA Masters theme. Hashoff has already completed a video-based social media content campaign for this client, with an NCAA March Madness tournament theme, and is expected to conduct similar campaigns around other major sporting event over the next months. The name of the brand has not been revealed, with DGTL only identifying it as a NASDAQ-listed company with a market capital of over $25 billion, and a leader in developing and commercializing mobile sports and fantasy sports betting applications that cover virtually all major professional sports leagues worldwide in fields such as racing, football, soccer, tennis, basketball, baseball, mixed martial arts and more. The digital sports entertainment and gaming sector is one of the several industries Hashoff and DGTL Holdings can serve successfully as more brands across every industry continue to shift from traditional advertising to digital media advertising at an accelerated rate. With a focus on building a full-service AI-powered digital media, marketing and advertising software platform, DGTL Holdings aims to position itself as a leading provider of diversified digital services and to create an extensive portfolio of content, distribution-based software and measurement technologies in several expanding areas such as gaming, social media, web advertising and streaming. For more information, visit the company’s website at www.DGTLInc.com. NOTE TO INVESTORS: The latest news and updates relating to DGTHF are available in the company’s newsroom at https://ibn.fm/DGTHF

• XPhyto Therapeutics Corp., a life sciences technology accelerator, is looking for ways to turn promising psychedelics into therapeutic pharmaceutical drugs, and recently added mescaline to its study profile
• Mescaline is illegal under U.S. federal law, but some state-centric efforts to legalize or decriminalize the hallucinogenic have launched in a manner similar to the populace effort that produced a wave of cannabis product legalization
• Mescaline has historically defied predictable outcomes by researchers, but advocates cite it as a means of successfully treating some mental health and substance abuse disorders
• A number of psychedelics production stocks saw huge gains during the past year

Bioscience industry innovator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) tapped into a ready market when it began the production and testing process for a rapid, point-of-care RT-PCR test system for COVID, but the Canada-based company raised eyebrows when it announced its Alberta subsidiary XPhyto Laboratories Inc., had added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/zQUC1). The small cap markets have seen the rise of several progressive psychedelics stocks over the past couple of years that further defined their sector as a potential growth area in 2020. Health Europa recently reported that Mind Medicine Inc saw its share price increase 864 percent last year, for example, and that Numinus Wellness increased 555 percent while Red Light Holland increased 300 percent, and that investors in several other psychedelic stocks saw their money double or triple during the year (https://ibn.fm/ymeR6). The report stated that some advocates believe psychedelics have much greater potential to disrupt the antidepressant market than cannabis, which has thus far failed to arrest the growth of antidepressant sales despite expectations to the contrary. Mescaline is listed in the United States’ federal drug registry as a hallucinogenic substance without legally recognized medicinal benefits that has a high risk of abuse, but the substance occurs naturally in some types of cactus and has been granted legal use under limited conditions pertaining to certain religious ceremonies registered by the Native American Church and in select research efforts. And much like cannabis, which saw its star rise as state after state defied U.S. federal drug policy by approving varied uses of hemp and cannabis within their political boundaries, mescaline has begun attracting legislative attention. In California, state Sen. Scott Wiener introduced a bill this year that would decriminalize select hallucinogenics, including mescaline, in part because he said research from top medical universities indicates that such substances can have significant benefits for treating mental health and substance use disorders. The bill passed the Senate Health Committee by a vote of 6-1 on April 14 and will now be reviewed by the Senate Appropriations Committee, according to a local CBS News affiliate report (https://ibn.fm/oWYut). Branded the world’s “first psychedelic” in a history about efforts to tame the drug for a variety of scientific and creative purposes (https://ibn.fm/iVmhR), mescaline has defied efforts to make it useful even since a synthetic version was created. However, this in turn creates a breakthrough opportunity for companies like XPhyto if they are able to make mescaline outcomes more predictable for its users, some of whom have historically reported euphoria and artistic enlightenment while others have reported serious nausea, anxiety and “excruciating” pain, according to the history. “We see a significant market opportunity in the production of pharmaceutical mescaline and the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use,” XPhyto CEO and Director Hugh Rogers stated in the company’s announcement. “Our goal is to develop industrial scale production processes for the wholesale market and for incorporation into XPhyto’s thin film drug delivery platforms.” For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• New York-based Ideanomics redefined its operations last year to synergistically create a global ecosystem focused on the growing potential of the electric vehicle market
• Ideanomics expects its developing revenue stream to largely depend on a Sales to Financing to Charging (S2F2C) business model based on vehicle and battery sales, financing and insurance services, and EV battery charging and related energy services
• Forecasts anticipate more than a million global commercial EV sales by 2023 and growth in the global EV charging infrastructure market at a CAGR of 33.4 percent from 2021 to 2028

Global commercial electric vehicle company Ideanomics (NASDAQ: IDEX) is driving next generation solutions to energy consumption. Through its Ideanomics Mobility division — the company has evolved into a synergistic ecosystem of subsidiaries and investments in the electric vehicle (“EV”) industry. We have a unique view across what we believe is the (‘EV’) value chain because we have operations in China, South Asia, in Malaysia, in Europe and in North America, and we have interesting subsidiaries and operations and investments in everything in the value chain from charging systems through the two-wheelers and three-wheelers, buses, trucks and even EV tractors on the agricultural side as well,” Ideanomics CEO Alf Poor said during a recent webinar on investments in the EV battery and charging markets (https://ibn.fm/A8A6h). The Mobility Division’s focus on the EV ecosystem is Ideanomics’ primary source of revenue following a shift during the past year. Ideanomics believes it has identified a significant strategic opportunity to grow within the PRC and globally in a changing economic climate that is trending toward renewable energies and reduced use of the internal combustion engine. The year-end report notes Bloomberg NEF estimates that global commercial EV sales will reach 1.2 million units in 2023 and that the global EV charging infrastructure market will grow at a compound annual growth rate of 33.4 percent from 2021 to 2028, achieving a $144.97 billion revenue stream. Ideanomics is developing a Sales to Financing to Charging (S2F2C) business model that relies on three revenue channels: vehicle and battery sales; financing, leasing and insurance services for fleet customers; and EV battery charging and energy services. Many of the company’s operations are in the development or early stage and have not had significant revenues to date. Ideanomics Mobility’s mission is to leverage its ecosystem of operating companies to use EV and EV battery sales and financing solutions to attract commercial fleet operators that will generate large-scale demand for energy, particularly through its operations in Asia at this time, operating as an end-to-end solutions provider for the procurement, financing, charging and energy management needs for fleet operators of commercial EV. Although Ideanomics’ principal revenue sources are in China, a nation that leads global EV trade thanks largely to government support of the industry, the company notes expectations for rising EV adoption elsewhere in the world amid forecasts that associated costs will decrease in the near future. Industry publication Utility Dive recently reported that the number of electric vehicle models available to U.S. consumers is expected to more than triple during the next three years as the industry achieves cost parity between internal combustion and EV ancillary solutions (https://ibn.fm/ZzGd1), and a February executive order signed by President Joe Biden highlighted the national leadership’s concern about finding the resources to sustain EV adoption independently of contracting supplies from China (https://ibn.fm/pnwo3). Ideanomics expects 2021 to be a growth year after it raised about $400 million during the last half of 2020, about half of which was used to acquire Wireless Advanced Vehicle Electrification (“WAVE”) and Timios. Utah-based WAVE is a leading provider of inductive (wireless) charging solutions for medium and heavy-duty EVs, which can be embedded in roadways and depot facilities and eliminate many of the limitations and hazards of plug-in-based charging systems. Timios, a nationwide title and escrow services provider, has been expanding in recent years through offering innovative and freedom-of-choice-friendly solutions for real estate transactions and is expected to become one of the cornerstones of Ideanomics’ Capital division. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• FingerMotion Inc. is made up of four business units, including a big-data insights (Sapientus) division
• Sapientus is poised to be the company’s leading revenue generator, alongside the rich communication services division
• FingerMotion partnered with Pacific Life Re-insurance, ushering it into the insuratech industry wherein it can monetize its big-data asset with a sellable product

MarketsandMarkets projects that the global big-data market size will grow to $229.4 billion by 2025, up from an estimated $138.9 billion in 2020. At a CAGR of 10.6%, this growth is driven by such factors as the increasing availability of data across organizations, knowledge of Internet of Things (“IoT”) devices among companies and government funding to enhance digital technologies (https://ibn.fm/HLiGM). The first driver can be considered a wheelhouse for FingerMotion (OTCQX: FNGR), an evolving technological company that has ventured into big data. Founded in 2016 as a mobile gaming company that later diversified into the mobile recharge business, citing stagnation, FNGR has grown over the years thanks to partnerships and relationships with large corporations in China, including Alibaba, JD.com, Pinduoduo, China Unicom, China Telecom and China Mobile. Presently, FingerMotion is made up of four business units: telecommunication products and services (its foundation business), SMS and MMS services, rich communication services (“RCS”) and big-data insights (https://ibn.fm/CjnW8). Though the former two divisions have long been the company’s primary revenue source, FNGR anticipates that once it formally launches the last two units in 2021, their revenues will eclipse those of their older counterparts. Notably, FingerMotion has already launched its big data insights division, dubbed Sapientus, through a partnership with Pacific Life Re-insurance. “In January, we made one of the most significant announcements as a company. We are very proud to announce our partnership with Pacific Life Re-insurance, in essence becoming their data provider,” FingerMotion CEO Martin J. Shen said in his presentation during the March 3 Emerging Growth Conference (https://ibn.fm/7bJBt). “We’re very excited about the deal because it not only validated the work, which we had had in our R&D phase for about two years, but also put us on track to monetize our data asset.” Shen also noted that the Sapientus division would offer more than just data. It will focus on providing behavioral analytics, with the resultant information giving more insight into human nature itself. Combined, these elements will add value to its clients, who will initially be drawn from the Chinese insuratech industry. Later, FingerMotion will extend Sapientus’ predictive algorithms and platform to finance, healthcare and insurance, as well as other jurisdictions. “We look to build strong forays into the insuratech space,” Shen said in a separate video update on the company’s activities in February (https://ibn.fm/OWCbd). “We believe other re-insurance companies will look to develop a similar model with us. By remaining non-exclusive and offering similar services to other companies in other insurance sectors, we believe we have the potential to be the most disruptive technology in insurance today.” In a market fraught with companies that know how to process data but not how to draw value from it through transformation and analysis, Shen was quick to point out that FingerMotion has the edge over such firms. It transforms the data by overlaying the information with its proprietary behavioral algorithms before applying it to specific industry applications. FNGR also differentiates itself from the competition because of its access to real data from actual users. The insurance industry in China has witnessed tremendous growth, with projections showing that it will be the largest insurance market in the next decade. The health insurance alone grew at a CAGR of over 12% from 1999 to 2019, with short-term health insurance, considered the fastest growing property and casualty insurance segment, witnessing a 47.4% year-over-year growth in 2019. However, according to Shen, this industry has remained relatively untapped. With the Pacific Life Re-Insurance partnership having ushered FingerMotion into the insuratech industry, its future remains bright. The company can offer its big data insights platform to other insuratech firms and generate revenue. Therefore, FNGR is on track to monetize its data asset with a sellable product. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR